JP5911723B2 - 細胞内に送達するためのジブロックコポリマーおよびそのポリヌクレオチド複合体 - Google Patents

細胞内に送達するためのジブロックコポリマーおよびそのポリヌクレオチド複合体 Download PDF

Info

Publication number
JP5911723B2
JP5911723B2 JP2011509670A JP2011509670A JP5911723B2 JP 5911723 B2 JP5911723 B2 JP 5911723B2 JP 2011509670 A JP2011509670 A JP 2011509670A JP 2011509670 A JP2011509670 A JP 2011509670A JP 5911723 B2 JP5911723 B2 JP 5911723B2
Authority
JP
Japan
Prior art keywords
alkyl
kda
polymer
group
block
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2011509670A
Other languages
English (en)
Japanese (ja)
Other versions
JP2011521054A (ja
JP2011521054A5 (enExample
Inventor
ステイトン、パトリック・エス．
ホフマン、アラン・エス．
コンバータイン、アンソニー・ジェイ．
ベノイト、ダニール
ドゥバル、クレイグ・エル．
ジョンソン、ポール
ガール、アンナ
Original Assignee
ユニヴァーシティ オブ ワシントン
ユニヴァーシティ オブ ワシントン
フェイズアールエックス，インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ユニヴァーシティ オブ ワシントン, ユニヴァーシティ オブ ワシントン, フェイズアールエックス，インコーポレイテッド filed Critical ユニヴァーシティ オブ ワシントン
Publication of JP2011521054A publication Critical patent/JP2011521054A/ja
Publication of JP2011521054A5 publication Critical patent/JP2011521054A5/ja
Application granted granted Critical
Publication of JP5911723B2 publication Critical patent/JP5911723B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08F—MACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
    • C08F293/00—Macromolecular compounds obtained by polymerisation on to a macromolecule having groups capable of inducing the formation of new polymer chains bound exclusively at one or both ends of the starting macromolecule
    • C08F293/005—Macromolecular compounds obtained by polymerisation on to a macromolecule having groups capable of inducing the formation of new polymer chains bound exclusively at one or both ends of the starting macromolecule using free radical "living" or "controlled" polymerisation, e.g. using a complexing agent
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08F—MACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
    • C08F299/00—Macromolecular compounds obtained by interreacting polymers involving only carbon-to-carbon unsaturated bond reactions, in the absence of non-macromolecular monomers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/58—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. poly[meth]acrylate, polyacrylamide, polystyrene, polyvinylpyrrolidone, polyvinylalcohol or polystyrene sulfonic acid resin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08F—MACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
    • C08F220/00—Copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and only one being terminated by only one carboxyl radical or a salt, anhydride ester, amide, imide or nitrile thereof
    • C08F220/02—Monocarboxylic acids having less than ten carbon atoms; Derivatives thereof
    • C08F220/10—Esters
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08F—MACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
    • C08F293/00—Macromolecular compounds obtained by polymerisation on to a macromolecule having groups capable of inducing the formation of new polymer chains bound exclusively at one or both ends of the starting macromolecule
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/111—General methods applicable to biologically active non-coding nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/10—Fusion polypeptide containing a localisation/targetting motif containing a tag for extracellular membrane crossing, e.g. TAT or VP22
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/32—Special delivery means, e.g. tissue-specific

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Polymers & Plastics (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Inorganic Chemistry (AREA)
  • Oncology (AREA)
  • Transplantation (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
JP2011509670A 2008-05-13 2009-05-13 細胞内に送達するためのジブロックコポリマーおよびそのポリヌクレオチド複合体 Expired - Fee Related JP5911723B2 (ja)

Applications Claiming Priority (19)

Application Number Priority Date Filing Date Title
US5291408P 2008-05-13 2008-05-13
US5290808P 2008-05-13 2008-05-13
US61/052,908 2008-05-13
US61/052,914 2008-05-13
US9129408P 2008-08-22 2008-08-22
US61/091,294 2008-08-22
US11205408P 2008-11-06 2008-11-06
US11204808P 2008-11-06 2008-11-06
US61/112,048 2008-11-06
US61/112,054 2008-11-06
US12076908P 2008-12-08 2008-12-08
US61/120,769 2008-12-08
US14077408P 2008-12-24 2008-12-24
US14077908P 2008-12-24 2008-12-24
US61/140,774 2008-12-24
US61/140,779 2008-12-24
US17137709P 2009-04-21 2009-04-21
US61/171,377 2009-04-21
PCT/US2009/043847 WO2009140427A2 (en) 2008-05-13 2009-05-13 Diblock copolymers and polynucleotide complexes thereof for delivery into cells

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2015200236A Division JP6239565B2 (ja) 2008-05-13 2015-10-08 細胞内に送達するためのジブロックコポリマーおよびそのポリヌクレオチド複合体

Publications (3)

Publication Number Publication Date
JP2011521054A JP2011521054A (ja) 2011-07-21
JP2011521054A5 JP2011521054A5 (enExample) 2012-07-05
JP5911723B2 true JP5911723B2 (ja) 2016-04-27

Family

ID=41319323

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2011509670A Expired - Fee Related JP5911723B2 (ja) 2008-05-13 2009-05-13 細胞内に送達するためのジブロックコポリマーおよびそのポリヌクレオチド複合体
JP2015200236A Active JP6239565B2 (ja) 2008-05-13 2015-10-08 細胞内に送達するためのジブロックコポリマーおよびそのポリヌクレオチド複合体

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2015200236A Active JP6239565B2 (ja) 2008-05-13 2015-10-08 細胞内に送達するためのジブロックコポリマーおよびそのポリヌクレオチド複合体

Country Status (13)

Country Link
US (3) US9476063B2 (enExample)
EP (2) EP2620161A1 (enExample)
JP (2) JP5911723B2 (enExample)
KR (1) KR101661636B1 (enExample)
CN (2) CN102083878B (enExample)
AU (1) AU2009246327B8 (enExample)
BR (1) BRPI0912159B8 (enExample)
CA (3) CA3065577C (enExample)
ES (1) ES2404131T3 (enExample)
IL (1) IL209238A (enExample)
MX (1) MX2010012238A (enExample)
WO (1) WO2009140427A2 (enExample)
ZA (1) ZA201008729B (enExample)

Families Citing this family (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2620161A1 (en) 2008-05-13 2013-07-31 University of Washington Diblock copolymers and polynucleotide complexes thereof for delivery into cells
CA2724014C (en) 2008-05-13 2016-09-13 University Of Washington Micellic assemblies
WO2009140421A2 (en) * 2008-05-13 2009-11-19 University Of Washington Polymeric carrier
EP2331069A4 (en) 2008-08-22 2011-10-26 Univ Washington HETEROGENIC POLYMIC MICELLES FOR INTRA-CELLULAR RELEASE
JP2012507581A (ja) 2008-11-06 2012-03-29 ユニヴァーシティ オブ ワシントン 二重特異性細胞内送達媒体
MX2011004242A (es) * 2008-11-06 2011-07-20 Univ Washington Copolimeros multibloque.
CA2745926A1 (en) 2008-12-08 2010-07-08 Phaserx, Inc. Omega-functionalized polymers, junction-functionalized block copolymers, polymer bioconjugates, and radical chain extension polymerization
WO2011060281A1 (en) * 2009-11-13 2011-05-19 University Of Washington Through Its Center For Commercialization Hydrophobic block conjugated therapeutic agents
WO2011062965A2 (en) 2009-11-18 2011-05-26 University Of Washington Through Its Center For Commercialization Targeting monomers and polymers having targeting blocks
US8349308B2 (en) 2010-03-26 2013-01-08 Mersana Therapeutics, Inc. Modified polymers for delivery of polynucleotides, method of manufacture, and methods of use thereof
EP3578205A1 (en) 2010-08-06 2019-12-11 ModernaTX, Inc. A pharmaceutical formulation comprising engineered nucleic acids and medical use thereof
CN103429606A (zh) 2010-10-01 2013-12-04 现代治疗公司 设计核酸及其使用方法
CA2831613A1 (en) 2011-03-31 2012-10-04 Moderna Therapeutics, Inc. Delivery and formulation of engineered nucleic acids
JP2014531476A (ja) 2011-08-26 2014-11-27 アローヘッド リサーチ コーポレイション インビボ核酸送達のためのポリ（ビニルエステル）ポリマー
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
AU2012308686B2 (en) * 2011-09-13 2018-05-10 Monsanto Technology Llc Methods and compositions for weed control
KR20190099538A (ko) 2011-10-03 2019-08-27 모더나 세라퓨틱스, 인코포레이티드 변형된 뉴클레오사이드, 뉴클레오타이드, 및 핵산, 및 이들의 용도
EP4144378A1 (en) 2011-12-16 2023-03-08 ModernaTX, Inc. Modified nucleoside, nucleotide, and nucleic acid compositions
US9572897B2 (en) 2012-04-02 2017-02-21 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
AU2013243954A1 (en) 2012-04-02 2014-10-30 Moderna Therapeutics, Inc. Modified polynucleotides for the production of cosmetic proteins and peptides
US9254311B2 (en) 2012-04-02 2016-02-09 Moderna Therapeutics, Inc. Modified polynucleotides for the production of proteins
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
CA2842041A1 (en) 2012-04-18 2013-10-24 Arrowhead Research Corporation Poly(acrylate) polymers for in vivo nucleic acid delivery
JP6195171B2 (ja) 2012-04-27 2017-09-13 国立大学法人 東京大学 核酸デリバリー用ユニット構造型医薬組成物
CA2873828A1 (en) 2012-05-24 2013-11-28 A.B. Seeds Ltd. Naked dsrna for silencing target molecules in plant seeds
US10046086B2 (en) 2012-09-21 2018-08-14 Vanderbilt University Poly(thioketal-urethane) scaffolds and methods of use
WO2014047524A1 (en) 2012-09-21 2014-03-27 Vanderbilt University Poly(thioketal-urethane) scaffolds and methods of use
DK2922554T3 (en) 2012-11-26 2022-05-23 Modernatx Inc Terminalt modificeret rna
US8980864B2 (en) 2013-03-15 2015-03-17 Moderna Therapeutics, Inc. Compositions and methods of altering cholesterol levels
US9867885B2 (en) 2013-07-30 2018-01-16 Phaserx, Inc. Block copolymers
US10023626B2 (en) 2013-09-30 2018-07-17 Modernatx, Inc. Polynucleotides encoding immune modulating polypeptides
BR112016007255A2 (pt) 2013-10-03 2017-09-12 Moderna Therapeutics Inc polinucleotídeos que codificam receptor de lipoproteína de baixa densidade
US20160303242A1 (en) 2013-12-09 2016-10-20 Durect Corporation Pharmaceutically Active Agent Complexes, Polymer Complexes, and Compositions and Methods Involving the Same
DK3116900T3 (da) 2014-03-09 2020-09-28 Univ Pennsylvania Sammensætninger som kan anvendes til behandling af ornithintranscarbamylase (otc) defekt
US11318206B2 (en) 2014-03-28 2022-05-03 Aposense Ltd Compounds and methods for trans-membrane delivery of molecules
CA2944141C (en) * 2014-03-28 2023-03-28 Aposense Ltd. Compounds and methods for trans-membrane delivery of molecules
US9993563B2 (en) * 2014-03-28 2018-06-12 Aposense Ltd. Compounds and methods for trans-membrane delivery of molecules
US10695288B2 (en) 2014-11-19 2020-06-30 Vanderbilt University Reactive oxygen species (ROS)-responsive compositions and methods thereof
AU2016209295B2 (en) * 2015-01-21 2021-08-12 Genevant Sciences Gmbh Methods, compositions, and systems for delivering therapeutic and diagnostic agents into cells
JP6929791B2 (ja) 2015-02-09 2021-09-01 デューク ユニバーシティ エピゲノム編集のための組成物および方法
JP6851319B2 (ja) 2015-04-27 2021-03-31 ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア ヒト疾患のＣＲＩＳＰＲ／Ｃａｓ９媒介性の修正のためのデュアルＡＡＶベクター系
WO2017015637A1 (en) 2015-07-22 2017-01-26 Duke University High-throughput screening of regulatory element function with epigenome editing technologies
EA201890565A1 (ru) 2015-08-25 2019-04-30 Дьюк Юниверсити Композиции и способы улучшения специфичности в геномной инженерии с применением рнк-направляемых эндонуклеаз
WO2017066497A2 (en) 2015-10-13 2017-04-20 Duke University Genome engineering with type i crispr systems in eukaryotic cells
EP3421517B1 (en) * 2016-03-29 2019-09-11 LG Chem, Ltd. Block polymer and polymer electrolyte membrane comprising same
US20190127713A1 (en) 2016-04-13 2019-05-02 Duke University Crispr/cas9-based repressors for silencing gene targets in vivo and methods of use
EP4275747A3 (en) 2016-07-19 2024-01-24 Duke University Therapeutic applications of cpf1-based genome editing
WO2018045317A1 (en) 2016-09-02 2018-03-08 Dicerna Pharmaceuticals, Inc. 4'-phosphate analogs and oligonucleotides comprising the same
US11684584B2 (en) 2016-12-30 2023-06-27 Genevant Sciences Gmbh Branched peg molecules and related compositions and methods
EA201991661A1 (ru) 2017-01-09 2019-12-30 Апосенс Лтд. Соединения и способы трансмембранной доставки молекул
EP3638215A4 (en) 2017-06-15 2021-03-24 Modernatx, Inc. RNA FORMULATIONS
EP3677268A4 (en) 2017-08-31 2021-04-21 The University Of Tokyo UNIT POLYIONIC COMPLEX FILLED WITH NUCLEIC ACID
CN111315359A (zh) 2017-08-31 2020-06-19 摩登纳特斯有限公司 制备脂质纳米颗粒的方法
US12337036B2 (en) 2018-01-01 2025-06-24 Aposense Ltd Compounds and methods for trans-membrane delivery of molecules
WO2020061457A1 (en) 2018-09-20 2020-03-26 Modernatx, Inc. Preparation of lipid nanoparticles and methods of administration thereof
WO2020092633A1 (en) * 2018-10-30 2020-05-07 Vanderbilt University Graft copolymers, methods of forming graft copolymers, and methods of use thereof
JP7389055B2 (ja) * 2019-01-09 2023-11-29 デンカ株式会社 トリブロック共重合体及びトリブロック共重合体の製造方法
AU2020253823A1 (en) 2019-03-29 2021-10-14 Dicerna Pharmaceuticals, Inc. Compositions and methods for the treatment of KRAS associated diseases or disorders
CA3136676A1 (en) 2019-05-03 2020-11-12 Dicerna Pharmaceuticals, Inc. Double-stranded nucleic acid inhibitor molecules with shortened sense strands
BR112022013821A2 (pt) 2020-01-15 2022-09-13 Dicerna Pharmaceuticals Inc Ácidos nucleicos de 4?-o-metileno fosfonato e seus análogos
EP4143248A1 (en) * 2020-04-30 2023-03-08 Dow Global Technologies LLC Process for preparing olefin-acrylate block copolymers by raft polyerization
US20230277675A1 (en) 2020-08-04 2023-09-07 Dicerna Pharmaceuticals, Inc. Systemic delivery of oligonucleotides
CN113087017A (zh) * 2021-04-06 2021-07-09 中国科学院理化技术研究所 一种偏钒酸钠纳米球及其制备方法和应用
JP2025524469A (ja) 2022-06-24 2025-07-30 チューン セラピューティクス インコーポレイテッド 標的を定めた遺伝子抑制を介して低密度リポタンパク質を低減するための組成物、系、及び方法
WO2025072751A1 (en) 2023-09-29 2025-04-03 Battelle Memorial Institute Polymer nanoparticle compositions for in vivo expression of polypeptides
WO2025072893A1 (en) 2023-09-29 2025-04-03 Battelle Memorial Institute Polymer nanoparticle compositions for non-viral gene delivery
WO2025250979A1 (en) 2024-05-31 2025-12-04 Battelle Memorial Institute Polymer nanoparticle compositions for non-viral gene delivery

Family Cites Families (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4699784A (en) 1986-02-25 1987-10-13 Center For Molecular Medicine & Immunology Tumoricidal methotrexate-antibody conjugate
US5057313A (en) 1986-02-25 1991-10-15 The Center For Molecular Medicine And Immunology Diagnostic and therapeutic antibody conjugates
US4877603A (en) 1987-12-18 1989-10-31 The Procter & Gamble Company Oral compositions
US6359054B1 (en) 1994-11-18 2002-03-19 Supratek Pharma Inc. Polynucleotide compositions for intramuscular administration
FR2767829B1 (fr) 1997-09-01 1999-12-03 Georges Sturtz Composes phosphonates ou gem-bisphosphonates acryliques ou methacryliques
US6410057B1 (en) 1997-12-12 2002-06-25 Samyang Corporation Biodegradable mixed polymeric micelles for drug delivery
AU740342B2 (en) 1997-12-12 2001-11-01 Samyang Corporation Biodegradable mixed polymeric micelles for gene delivery
US6383811B2 (en) 1997-12-30 2002-05-07 Mirus Corporation Polyampholytes for delivering polyions to a cell
EP2138191A1 (en) 1998-01-05 2009-12-30 University Of Washington Enhanced transport using membrane disruptive agents
US6306994B1 (en) * 1999-05-14 2001-10-23 E. I. Du Pont De Nemours And Company Inks with enhanced substrate binding characteristics
US7098032B2 (en) 2001-01-02 2006-08-29 Mirus Bio Corporation Compositions and methods for drug delivery using pH sensitive molecules
US7033607B2 (en) 1999-12-31 2006-04-25 Mirus Bio Corporation pH-titratable polyampholytes for delivering polyions to a cell
WO2001051092A2 (en) 2000-01-07 2001-07-19 University Of Washington Enhanced transport of agents using membrane disruptive agents
US20030134420A1 (en) 2000-02-18 2003-07-17 Lollo Charles Peter Methods and compositions for gene delivery
WO2001087227A2 (en) 2000-05-17 2001-11-22 Labopharm, Inc. Drug containing polymeric micelles
SE517421C2 (sv) 2000-10-06 2002-06-04 Bioglan Ab Mikropartiklar, lämpade för parenteral administration, väsentligen bestående av stärkelse med minst 85 % amylopektin och med reducerad molekylvikt, samt framställning därav
ATE365753T1 (de) 2000-10-06 2007-07-15 Biocompatibles Uk Ltd Zwitterionische polymere
AU2002367709A1 (en) 2001-04-26 2003-10-27 Nanosphere, Inc. Oligonucleotide-modified romp polymers and co-polymers
US7094810B2 (en) 2001-06-08 2006-08-22 Labopharm, Inc. pH-sensitive block copolymers for pharmaceutical compositions
US6939564B2 (en) 2001-06-08 2005-09-06 Labopharm, Inc. Water-soluble stabilized self-assembled polyelectrolytes
US6780428B2 (en) 2001-06-08 2004-08-24 Labopharm, Inc. Unimolecular polymeric micelles with an ionizable inner core
WO2003059382A2 (en) 2001-12-28 2003-07-24 Supratek Pharma Inc. Pharmaceutical compositions comprising polyanionic polymers and amphiphilic block copolymers and methods of use thereof to improve gene expression
US20050220880A1 (en) 2002-03-07 2005-10-06 Lewis Andrew L Drug carriers comprising amphiphilic block copolymers
US7229973B2 (en) 2002-05-19 2007-06-12 You Han Bae pH-sensitive polymeric micelles for drug delivery
EP1400555A1 (en) 2002-09-17 2004-03-24 Kawamura Institute Of Chemical Research Water-soluble block copolymer and production method therefor
EP1558658B1 (fr) 2002-11-07 2012-12-19 Rhodia Chimie Copolymere a structure controlee presentant une partie amphotere ou zwitterionique.
US20070010632A1 (en) 2002-11-27 2007-01-11 Kaplan David L Antioxidant-functionalized polymers
CN100349963C (zh) 2002-12-30 2007-11-21 尼克塔治疗亚拉巴马公司 作为药物输送媒介物的多分支多肽－聚(乙二醇)嵌段共聚物
US7871818B2 (en) 2003-01-31 2011-01-18 Roche Madison Inc. Membrane active polymers
US7217776B1 (en) 2003-02-14 2007-05-15 Iowa State University Research Foundation pH-sensitive methacrylic copolymer gels and the production thereof
US20040162235A1 (en) 2003-02-18 2004-08-19 Trubetskoy Vladimir S. Delivery of siRNA to cells using polyampholytes
JP4535229B2 (ja) 2003-05-08 2010-09-01 国立大学法人 東京大学 ポリエチレングリコール−ポリカチオンブロック共重合体
US7632905B2 (en) 2004-04-09 2009-12-15 L'oreal S.A. Block copolymer, composition comprising it and cosmetic treatment process
FR2868784B1 (fr) * 2004-04-09 2006-05-26 Oreal Copolymere sequence, composition le comprenant et procede de traitement cosmetique
WO2005108614A2 (en) 2004-04-07 2005-11-17 Northwestern University Reversible and chemically programmable micelle assembly with dna block-copolymer amphiphiles
US8821859B2 (en) 2004-05-19 2014-09-02 Agency For Science, Technology And Research Methods and articles for the delivery of therapeutic agents
GB0418123D0 (en) * 2004-08-13 2004-09-15 Asahi Chemical Ind Polymers useful as medical materials
US20060134221A1 (en) 2004-12-03 2006-06-22 Vical Incorporated Methods for producing block copolymer/amphiphilic particles
US20060165810A1 (en) 2004-12-28 2006-07-27 The Trustees Of The University Of Pennsylvania Controlled release from block co-polymer worm micelles
US20060171980A1 (en) 2005-02-01 2006-08-03 Helmus Michael N Implantable or insertable medical devices having optimal surface energy
US20060235161A1 (en) 2005-03-31 2006-10-19 Jorge Heller PEG-polyacetal and PEG-polyacetal-POE graft copolymers and pharmaceutical compositions
US20080171067A1 (en) 2007-01-17 2008-07-17 Immunomedics, Inc. Polymeric Carriers of Therapeutic Agents and Recognition Moieties for Antibody-Based Targeting of Disease Sites
CA2604696C (en) 2005-04-15 2015-03-24 Interface Biologics, Inc. Polymer-biologically active agent complexes for localized delivery of said biologically active agent
US9139850B2 (en) 2005-05-19 2015-09-22 L'oreal Vectorization of dsRNA by cationic particles and topical use
EP1891141B1 (en) 2005-05-31 2016-11-16 Ecole Polytechnique Fédérale de Lausanne (EPFL) Triblock copolymers for cytoplasmic delivery of gene-based drugs
FR2890859B1 (fr) 2005-09-21 2012-12-21 Oreal Oligonucleotide d'arn double brin inhibant l'expression de la tyrosinase
US7718193B2 (en) * 2006-03-16 2010-05-18 University Of Washington Temperature- and pH-responsive polymer compositions
EP2019691B1 (en) 2006-05-15 2020-08-12 Massachusetts Institute of Technology Polymers for functional particles
WO2008004978A1 (en) 2006-07-05 2008-01-10 Agency For Science, Technology And Research Micelles for drug delivery
CN101500548A (zh) 2006-08-18 2009-08-05 弗·哈夫曼-拉罗切有限公司 用于体内递送多核苷酸的多缀合物
WO2008085556A2 (en) 2006-09-12 2008-07-17 University Of South Florida Surfactant-free nanoparticles for drug delivery
US20080081075A1 (en) 2006-10-02 2008-04-03 National Tsing Hua University Multifunctional mixed micelle of graft and block copolymers and preparation thereof
US20100137206A1 (en) 2006-12-15 2010-06-03 The Governors Of The University Of Alberta Novel ligand guided block copolymers for targeted drug delivery
US20080311045A1 (en) 2007-06-06 2008-12-18 Biovaluation & Analysis, Inc. Polymersomes for Use in Acoustically Mediated Intracellular Drug Delivery in vivo
WO2008148174A1 (en) 2007-06-08 2008-12-11 Queensland University Of Technology Wound repair composition and method
WO2008153940A1 (en) 2007-06-11 2008-12-18 Biocure, Inc. Vesicles for active macromolecule delivery
EP2171095A4 (en) 2007-07-06 2012-07-11 Univ Northeastern MIXED MICELLES WITH AMPHIPATHIC CONJUGATES FROM RNA ACTIVE SUBSTANCES AND USES THEREOF
US20090036625A1 (en) 2007-08-01 2009-02-05 Chung Yuan Christian University Amphiphilic Polymer, Method for Forming the Same and Application thereof
EP2025348A1 (en) 2007-08-13 2009-02-18 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Targeted block copolymer micelles
EP2620161A1 (en) 2008-05-13 2013-07-31 University of Washington Diblock copolymers and polynucleotide complexes thereof for delivery into cells
EP2296627A2 (en) 2008-05-13 2011-03-23 The University of Washington Micelles for intracellular delivery of therapeutic agents
WO2009140421A2 (en) 2008-05-13 2009-11-19 University Of Washington Polymeric carrier
WO2009140423A2 (en) 2008-05-13 2009-11-19 University Of Washington Targeted polymer bioconjugates
CA2724014C (en) 2008-05-13 2016-09-13 University Of Washington Micellic assemblies
EP2331069A4 (en) 2008-08-22 2011-10-26 Univ Washington HETEROGENIC POLYMIC MICELLES FOR INTRA-CELLULAR RELEASE
ES2366758T3 (es) 2008-10-22 2011-10-25 Clariant Finance (Bvi) Limited Compuestos de fosfonato olefínicamente insaturados, polímeros fabricados a partir de ellos, y su uso.
US20110281934A1 (en) 2008-11-06 2011-11-17 Phaserx, Inc. Micelles of hydrophilically shielded membrane-destabilizing copolymers
JP2012507581A (ja) 2008-11-06 2012-03-29 ユニヴァーシティ オブ ワシントン 二重特異性細胞内送達媒体
MX2011004242A (es) 2008-11-06 2011-07-20 Univ Washington Copolimeros multibloque.
US20100150952A1 (en) 2008-11-07 2010-06-17 University Of Washington pH-RESPONSIVE POLYMER CARRIER COMPOSITIONS FOR CYTOSOLIC PROTEIN DELIVERY
CA2745926A1 (en) 2008-12-08 2010-07-08 Phaserx, Inc. Omega-functionalized polymers, junction-functionalized block copolymers, polymer bioconjugates, and radical chain extension polymerization

Also Published As

Publication number Publication date
BRPI0912159A2 (pt) 2015-10-13
JP6239565B2 (ja) 2017-11-29
CA2724105A1 (en) 2009-11-19
CN102083878A (zh) 2011-06-01
JP2016053169A (ja) 2016-04-14
CA2972694C (en) 2020-02-11
CA3065577A1 (en) 2009-11-19
BRPI0912159B1 (pt) 2019-11-05
CA3065577C (en) 2022-05-31
US9476063B2 (en) 2016-10-25
US20170096517A1 (en) 2017-04-06
WO2009140427A2 (en) 2009-11-19
US20180171056A1 (en) 2018-06-21
IL209238A0 (en) 2011-01-31
EP2620161A1 (en) 2013-07-31
EP2281011B1 (en) 2013-02-27
CA2724105C (en) 2017-09-05
EP2281011A4 (en) 2011-10-26
KR101661636B1 (ko) 2016-09-30
CA2972694A1 (en) 2009-11-19
ZA201008729B (en) 2014-05-28
US20110143434A1 (en) 2011-06-16
KR20110033124A (ko) 2011-03-30
AU2009246327B2 (en) 2013-09-12
CN103342789A (zh) 2013-10-09
AU2009246327A8 (en) 2011-01-13
US9862792B2 (en) 2018-01-09
MX2010012238A (es) 2011-04-11
CN102083878B (zh) 2013-07-10
ES2404131T3 (es) 2013-05-24
IL209238A (en) 2014-03-31
JP2011521054A (ja) 2011-07-21
AU2009246327A1 (en) 2009-11-19
BRPI0912159B8 (pt) 2021-05-25
WO2009140427A3 (en) 2010-03-04
EP2281011A2 (en) 2011-02-09
AU2009246327B8 (en) 2013-10-03
CN103342789B (zh) 2016-11-23

Similar Documents

Publication Publication Date Title
JP6239565B2 (ja) 細胞内に送達するためのジブロックコポリマーおよびそのポリヌクレオチド複合体
KR101764427B1 (ko) 미셀성 어셈블리
EP2364330B1 (en) Multiblock copolymers
JP2011523641A (ja) 高分子キャリア
KR20110020804A (ko) 치료제의 세포내 전달을 위한 미셀
AU2013204733B2 (en) Diblock copolymers and polynucleotide complexes thereof for delivery into cells
Zhou Design of polymer motifs for nucleic acid recognition and assembly stabilization

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120514

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20120514

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20130307

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20130416

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20130708

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20130716

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20131016

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20140624

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20140919

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20140929

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20141222

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20150609

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20151008

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20151016

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20151117

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160128

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20160301

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20160330

R150 Certificate of patent or registration of utility model

Ref document number: 5911723

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees